A UK national commission published a blueprint to tailor regulation of AI in healthcare, urging the Medicines and Healthcare products Regulatory Agency (MHRA) to update oversight beyond a one-time premarket approval model. The report argues AI-enabled products may iterate rapidly and perform differently across settings, requiring life-cycle governance that better matches how these systems behave in real-world use. The recommendations call for oversight mechanisms that account for data, workflows, and the people organizations involved. For biotech and digital health developers, the approach signals tighter expectations around monitoring, post-deployment change control, and evidence stewardship for AI-based medical devices.